Blood-brain-barriers in aging and in Alzheimer's disease

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Marques, Fernanda ^a,b   Sousa, João Carlos ^a,b   Sousa, Nuno ^a,b   Palha, Joana Almeida ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

Author keywords

Aging; Alzheimer's disease; Blood brain barrier; Blood cerebrospinal fluid barrier; Cerebrospinal fluid; Choroid plexus

Indexed keywords

AMYLOID PRECURSOR PROTEIN; INSULIN; LEPTIN; TRANSFERRIN;

AGING; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN CAPILLARY; BRAIN FUNCTION; BRAIN METABOLISM; CELL MIGRATION; CHOROID PLEXUS; DENDRITIC CELL; ENDOTHELIUM CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; INFLAMMATION; INTERSTITIAL FLUID; MACROPHAGE; MEMBRANE PERMEABILITY; PROTEIN HOMEOSTASIS; REVIEW; TIGHT JUNCTION;

AGING; ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; HUMANS;

EID: 84886907892     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-38     Document Type: Review

References (101)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM: Forecasting the global burden of Alzheimer 's disease. Alzheimers Dement 2007, 3:186-191.
2. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
3. Sotiropoulos I, Catania C, Pinto LG, Silva R, Pollerberg GE, Takashima A, Sousa N, Almeida OF: Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits. J Neurosci 2011, 31:7840-7847.
4. Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, Cesari M, Nourhashemi F: Proinflammatory Cytokines, Aging, and Age-Related Diseases. J Am Med Dir Assoc 2013, S1525-8610(13):00280-00286.
5. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ: Structure and function of the blood-brain barrier. Neurobiol Dis 2010, 37:13-25.
6. Engelhardt B, Coisne C: Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS 2011, 8:4.
7. Greenwood J, Heasman SJ, Alvarez JI, Prat A, Lyck R, Engelhardt B: Review: leucocyte-endothelial cell crosstalk at the blood-brain barrier: a prerequisite for successful immune cell entry to the brain. Neuropathol Appl Neurobiol 2011, 37:24-39.
8. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, et al: The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011, 477:90-94.
9. Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, Fang WG, Zhu L, Chen YH: Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease. Neurobiol Aging 2007, 28:485-496.
10. Liu YJ, Guo DW, Tian L, Shang DS, Zhao WD, Li B, Fang WG, Zhu L, Chen YH: Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent. Neurobiol Aging 2010, 31:175-188.
11. Langlet F, Mullier A, Bouret SG, Prevot V, Dehouck B: Tanycyte-like cells form a blood-cerebrospinal fluid barrier in the circumventricular organs of the mouse brain. J Comp Neurol 2013, 521:3389-3405.
12. Begley DJ, Brightman MW: Structural and functional aspects of the blood-brain barrier. Prog Drug Res 2003, 61:39-78.
13. Pardridge WM, Eisenberg J, Yang J: Human blood-brain barrier insulin receptor. J Neurochem 1985, 44:1771-1778.
14. Zhang Y, Pardridge WM: Rapid transferrin efflux from brain to blood across the blood-brain barrier. J Neurochem 2001, 76:1597-1600.
15. Zlokovic BV: The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.
16. Dziegielewska KM, Ek J, Habgood MD, Saunders NR: Development of the choroid plexus. Microsc Res Tech 2001, 52:5-20.
17. Saunders NR, Daneman R, Dziegielewska KM, Liddelow SA: Transporters of the blood-brain and blood-CSF interfaces in development and in the adult. Mol Aspects Med 2013, 34:742-752.
18. Speake T, Whitwell C, Kajita H, Majid A, Brown PD: Mechanisms of CSF secretion by the choroid plexus. Microsc Res Tech 2001, 52:49-59.
19. Segal MB: Transport of nutrients across the choroid plexus. Microsc Res Tech 2001, 52:38-48.
20. Marques F, Sousa JC, Coppola G, Falcao AM, Rodrigues AJ, Geschwind DH, Sousa N, Correia-Neves M, Palha JA: Kinetic profile of the transcriptome changes induced in the choroid plexus by peripheral inflammation. J Cereb Blood Flow Metab 2009, 29:921-932.
21. Marques F, Sousa JC, Coppola G, Geschwind DH, Sousa N, Palha JA, Correia-Neves M: The choroid plexus response to a repeated peripheral inflammatory stimulus. BMC Neurosci 2009, 10:135.
22. Rivest S, Lacroix S, Vallieres L, Nadeau S, Zhang J, Laflamme N: How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 2000, 223:22-38.
23. Sagare AP, Bell RD, Zlokovic BV: Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2:a011452.
24. Bell RD, Zlokovic BV: Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009, 118:103-113.
25. Brown WR, Thore CR: Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol 2011, 37:56-74.
26. Stoquart-ElSankari S, Baledent O, Gondry-Jouet C, Makki M, Godefroy O, Meyer ME: Aging effects on cerebral blood and cerebrospinal fluid flows. J Cereb Blood Flow Metab 2007, 27:1563-1572.
27. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV: Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010, 68:409-427.
28. Winkler EA, Bell RD, Zlokovic BV: Central nervous system pericytes in health and disease. Nat Neurosci 2011, 14:1398-1405.
29. Emerich DF, Skinner SJ, Borlongan CV, Vasconcellos AV, Thanos CG: The choroid plexus in the rise, fall and repair of the brain. Bioessays 2005, 27:262-274.
30. Serot JM, Bene MC, Faure GC: Choroid plexus, aging of the brain, and Alzheimer's disease. Front Biosci 2003, 8:s515-s521.
31. Preston JE: Ageing choroid plexus-cerebrospinal fluid system. Microsc Res Tech 2001, 52:31-37.
32. Wen GY, Wisniewski HM, Kascsak RJ: Biondi ring tangles in the choroid plexus of Alzheimer's disease and normal aging brains: a quantitative study. Brain Res 1999, 832:40-46.
33. Chiu C, Miller MC, Caralopoulos IN, Worden MS, Brinker T, Gordon ZN, Johanson CE, Silverberg GD: Temporal course of cerebrospinal fluid dynamics and amyloid accumulation in the aging rat brain from three to thirty months. Fluids Barriers CNS 2012, 9:3.
34. May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI: Cerebrospinal fluid production is reduced in healthy aging. Neurology 1990, 40:500-503.
35. Serot JM, Zmudka J, Jouanny P: A possible role for CSF turnover and choroid plexus in the pathogenesis of late onset Alzheimer's disease. J Alzheimers Dis 2012, 30:17-26.
36. Farrall AJ, Wardlaw JM: Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging 2009, 30:337-352.
37. Zlokovic BV: Clearing amyloid through the blood-brain barrier. J Neurochem 2004, 89:807-811.
38. Marques F, Falcao AM, Sousa JC, Coppola G, Geschwind D, Sousa N, Correia-Neves M, Palha JA: Altered iron metabolism is part of the choroid plexus response to peripheral inflammation. Endocrinology 2009, 150:2822-2828.
39. Walsh DM, Selkoe DJ: A beta oligomers - a decade of discovery. J Neurochem 2007, 101:1172-1184.
40. Benilova I, Karran E, De Strooper B: The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012, 15:349-357.
41. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B: Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat Med 2000, 6:718.
42. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, et al: A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012, 122:1377-1392.
43. Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar SS, Stopa EG, Donahue JE, Johanson CE: Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol 2010, 69:1034-1043.
44. van Assema DM, Lubberink M, Boellaard R, Schuit RC, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN: P-glycoprotein function at the blood-brain barrier: effects of age and gender. Mol Imaging Biol 2012, 14:771-776.
45. van Assema DM, Lubberink M, Rizzu P, van Swieten JC, Schuit RC, Eriksson J, Scheltens P, Koepp M, Lammertsma AA, van Berckel BN: Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene. EJNMMI Res 2012, 2:57.
46. Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I: Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J Neurosci 2005, 25:10884-10893.
47. Pascale CL, Miller MC, Chiu C, Boylan M, Caralopoulos IN, Gonzalez L, Johanson CE, Silverberg GD: Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids Barriers CNS 2011, 8:21.
48. Ingbar SH: Pre-albumin: a thyroxinebinding protein of human plasma. Endocrinology 1958, 63:256-259.
49. Dickson PW, Aldred AR, Marley PD, Bannister D, Schreiber G: Rat choroid plexus specializes in the synthesis and the secretion of transthyretin (prealbumin). Regulation of transthyretin synthesis in choroid plexus is independent from that in liver. J Biol Chem 1986, 261:3475-3478.
50. Sousa JC, Cardoso I, Marques F, Saraiva MJ, Palha JA: Transthyretin and Alzheimer's disease: where in the brain? Neurobiol Aging 2007, 28:713-718.
51. Palha JA: Transthyretin as a thyroid hormone carrier: function revisited. Clin Chem Lab Med 2002, 40:1292-1300.
52. Palha JA, Hays MT, Morreale de Escobar G, Episkopou V, Gottesman ME, Saraiva MJ: Transthyretin is not essential for thyroxine to reach the brain and other tissues in transthyretin-null mice. Am J Physiol 1997, 272:E485-E493.
53. Wei S, Episkopou V, Piantedosi R, Maeda S, Shimada K, Gottesman ME, Blaner WS: Studies on the metabolism of retinol and retinol-binding protein in transthyretin-deficient mice produced by homologous recombination. J Biol Chem 1995, 270:866-870.
54. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M: Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol 2004, 189:380-392.
55. Takasaki J, Ono K, Yoshiike Y, Hirohata M, Ikeda T, Morinaga A, Takashima A, Yamada M: Vitamin A has anti-oligomerization effects on amyloid-beta in vitro. J Alzheimers Dis 2011, 27:271-280.
56. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, et al: Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A 1994, 91:8368-8372.
57. Golabek A, Marques MA, Lalowski M, Wisniewski T: Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett 1995, 191:79-82.
58. Buxbaum J, Koziol J, Connors LH: Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. Amyloid 2008, 15:255-261.
59. Li X, Buxbaum JN: Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener 2011, 6:79.
60. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T: Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A 2008, 105:2681-2686.
61. Choi SH, Leight SN, Lee VM, Li T, Wong PC, Johnson JA, Saraiva MJ, Sisodia SS: Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci 2007, 27:7006-7010.
62. Wati H, Kawarabayashi T, Matsubara E, Kasai A, Hirasawa T, Kubota T, Harigaya Y, Shoji M, Maeda S: Transthyretin accelerates vascular Abeta deposition in a mouse model of Alzheimer's disease. Brain Pathol 2009, 19:48-57.
63. Sousa JC, Marques F, Dias-Ferreira E, Cerqueira JJ, Sousa N, Palha JA: Transthyretin influences spatial reference memory. Neurobiol Learn Mem 2007, 88:381-385.
64. Serot JM, Christmann D, Dubost T, Couturier M: Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 1997, 63:506-508.
65. Ribeiro CA, Santana I, Oliveira C, Baldeiras I, Moreira J, Saraiva MJ, Cardoso I: Transthyretin decrease in plasma of MCI and AD patients: investigation of mechanisms for disease modulation. Curr Alzheimer Res 2012, 9:881-889.
66. Palha JA, Moreira P, Wisniewski T, Frangione B, Saraiva MJ: Transthyretin gene in Alzheimer's disease patients. Neurosci Lett 1996, 204:212-214.
67. Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J: Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech 2000, 50:305-315.
68. Marques F, Sousa JC, Coppola G, Gao F, Puga R, Brentani H, Geschwind DH, Sousa N, Correia-Neves M, Palha JA: Transcriptome signature of the adult mouse choroid plexus. Fluids Barriers CNS 2011, 8:10.
69. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, et al : Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41:1088-1093.
70. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, et al : Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010, 67:739-748.
71. Silajdzic E, Minthon L, Bjorkqvist M, Hansson O: No diagnostic value of plasma clusterin in Alzheimer's disease. PLoS ONE 2012, 7:e50237.
72. Howlett DR, Hortobagyi T, Francis PT: Clusterin Associates Specifically with Abeta40 in Alzheimer's Disease Brain Tissue. Brain Pathol 2013. 10.1111/bpa.12057.
73. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J: Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A 1996, 93:4229-4234.
74. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I: Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 2002, 8:1390-1397.
75. Christensen EI, Birn H: Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 2002, 3:256-266.
76. Orlando RA, Rader K, Authier F, Yamazaki H, Posner BI, Bergeron JJ, Farquhar MG: Megalin is an endocytic receptor for insulin. J Am Soc Nephrol 1998, 9:1759-1766.
77. Carro E, Trejo JL, Gerber A, Loetscher H, Torrado J, Metzger F, Torres-Aleman I: Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging 2006, 27:1250-1257.
78. Pellicano M, Larbi A, Goldeck D, Colonna-Romano G, Buffa S, Bulati M, Rubino G, Iemolo F, Candore G, Caruso C, et al: Immune profiling of Alzheimer patients. J Neuroimmunol 2012, 242:52-59.
79. Sardi F, Fassina L, Venturini L, Inguscio M, Guerriero F, Rolfo E, Ricevuti G: Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly. Autoimmun Rev 2011, 11:149-153.
80. Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P: Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol 2009, 210:3-12.
81. Lee CY, Landreth GE: The role of microglia in amyloid clearance from the AD brain. J Neural Transm 2010, 117:949-960.
82. Yu D, Corbett B, Yan Y, Zhang GX, Reinhart P, Cho SJ, Chin J: Early cerebrovascular inflammation in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 2012, 33:2942-2947.
83. Kalaria RN: Vascular factors in Alzheimer's disease. Int Psychogeriatr 2003, 15(Suppl 1):47-52.
84. Kalaria RN: Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 2010, 68(Suppl 2):S74-S87.
85. Tripathy D, Sanchez A, Yin X, Luo J, Martinez J, Grammas P: Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia. Front Aging Neurosci 2013, 5:19.
86. Grammas P, Ovase R: Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol Aging 2001, 22:837-842.
87. Grammas P, Ovase R: Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer's disease brain. Am J Pathol 2002, 160:1583-1587.
88. Grammas P, Samany PG, Thirumangalakudi L: Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. J Alzheimers Dis 2006, 9:51-58.
89. Takeda S, Sato N, Ikimura K, Nishino H, Rakugi H, Morishita R: Increased blood-brain barrier vulnerability to systemic inflammation in an Alzheimer disease mouse model. Neurobiol Aging 2013, 34:2064-2070.
90. Herber DL, Mercer M, Roth LM, Symmonds K, Maloney J, Wilson N, Freeman MJ, Morgan D, Gordon MN: Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharmacol 2007, 2:222-231.
91. Marques F, Rodrigues AJ, Sousa JC, Coppola G, Geschwind DH, Sousa N, Correia-Neves M, Palha JA: Lipocalin 2 is a choroid plexus acute-phase protein. J Cereb Blood Flow Metab 2008, 28:450-455.
92. Kjeldsen L, Cowland JB, Borregaard N: Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 2000, 1482:272-283.
93. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S, Aderem A: Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004, 432:917-921.
94. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, et al: An iron-responsive element type II in the 5́-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002, 277:45518-45528.
95. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, et al: Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010, 142:857-867.
96. Liu B, Moloney A, Meehan S, Morris K, Thomas SE, Serpell LC, Hider R, Marciniak SJ, Lomas DA, Crowther DC: Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J Biol Chem 2011, 286:4248-4256.
97. Choi J, Lee HW, Suk K: Increased plasma levels of lipocalin 2 in mild cognitive impairment. J Neurol Sci 2011, 305:28-33.
98. Naude PJ, Nyakas C, Eiden LE, Ait-Ali D, van der Heide R, Engelborghs S, Luiten PG, De Deyn PP, den Boer JA, Eisel UL: Lipocalin 2: novel component of proinflammatory signaling in Alzheimer's disease. Faseb J 2012, 26:2811-2823.
99. Ferreira AC, Pinto V, Da Mesquita S, Novais A, Sousa JC, Correia-Neves M, Sousa N, Palha JA, Marques F: Lipocalin-2 is involved in emotional behaviors and cognitive function. Front Cell Neurosci 2013, 7:122.
100. Mucha M, Skrzypiec AE, Schiavon E, Attwood BK, Kucerova E, Pawlak R: Lipocalin-2 controls neuronal excitability and anxiety by regulating dendritic spine formation and maturation. Proc Natl Acad Sci U S A 2011, 108:18436-18441.
101. Skrzypiec AE, Shah RS, Schiavon E, Baker E, Skene N, Pawlak R, Mucha M: Stress-induced lipocalin-2 controls dendritic spine formation and neuronal activity in the amygdala. PLoS ONE 2013, 8:e61046.